Nephrology Times
Advertisement
In the phase 3 REGENCY trial, adding obinutuzumab to standard therapy for lupus nephritis led to better renal outcomes.
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Drs. Peter Richardson and George Wan of Mallinckrodt Pharmaceuticals discussed new data on terlipressin for HRS-AKI.
Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
The American Society of Nephrology (ASN) will create a Centers of Excellence in Home Dialysis pilot program.
Chris Klug, Timothy Caulfield, Borys Todurov, and Hongkui Deng will be keynote speakers at the World Transplant Congress.
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Researchers fitted a face mask with a breath sensor that may be able to detect the presence of chronic kidney disease.
This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD).
Several genetically predicted environmental factors increase the risk of IgAN and membranous nephropathy, a study found.
Researchers examined the effects of the GLP-1RA cotadutide on UACR, glycemic control, and body weight.
A meta-analysis examined the risk of CKD in patients with metabolic dysfunction-associated fatty liver disease.
An analysis Identified SIRT1, BAG3, COKN1A and FOS as potential autophagy-related biomarkers for IgAN.
Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy to help with risk stratification.
Researchers sought to quantify the population at risk for pruritus, clinical determinants, and associated adverse outcomes.
Ajay Singh talks dialytrauma—harmful effects of dialysis in patients with AKI moving from inpatient to outpatient care.
Sarah Tolson reviews how changes to reimbursement for phosphate binders have affected dialysis programs.
A study assessed whether proton pump inhibitor use accelerated CKD progression and acute kidney injury risk.
Dr. Pranav Garimella, CMO of the American Kidney Fund, discussed AMKD awareness and the importance of APOL1 gene variants.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.